MedPath

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Registration Number
NCT01381471
Lead Sponsor
GlaxoSmithKline
Brief Summary

The specific aim of this study is to describe 1 year Advair dispensing rates for patients with COPD, and to measure the association between Advair adherence and healthcare utilization (e.g. emergency room visits and inpatient admissions, etc.). To compare the risk of a COPD exacerbation (moderate or severe) during a 3-month follow-up period between patients thqat are adherent versus those that are not.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
11060
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
COPDfluticasone propionate/salmeterol xinafoate combinationPatients with a diagnosis code of COPD
Primary Outcome Measures
NameTimeMethod
Mean Number of Pharmacy Claims by Participants During the Post-Index PeriodOne Year

The mean number of pharmacy claims incurred by participants during the one-year post-index period was measured.

Mean Number of Healthcare Encounters Incurred by Participants During the Post-Index PeriodOne Year

The mean number of outpatient office visits, inpatient visits, and emergency department visits incurred by participants during the one-year post-index period was measured.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath